Management of hepatitis B reactivation in patients receiving cancer chemotherapy

Yi Wen Huang, Raymond T. Chung

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) reactivation is well documented in previously resolved or inactive HBV carriers who receive cancer chemotherapy. The consequences of HBV reactivation range from self-limited conditions to fulminant hepatic failure and death. HBV reactivation also leads to premature termination of chemotherapy or delay in treatment schedules. This review summarizes current knowledge of management of HBV reactivation in patients receiving cancer chemotherapy. HBV surface antigen (HBsAg) testing should be performed in patients who require cancer chemotherapy. Four meta-analyses support lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients. Randomized controlled trials to compare different HBV antiviral agents are needed to define optimal regimens for the prevention and treatment of HBV reactivation in patients receiving cancer chemotherapy.

Original languageEnglish
Pages (from-to)359-370
Number of pages12
JournalTherapeutic Advances in Gastroenterology
Volume5
Issue number5
DOIs
Publication statusPublished - Sep 2012
Externally publishedYes

Keywords

  • Cancer
  • Chemotherapy
  • HBV reactivation
  • Hepatitis B virus
  • Lamivudine
  • Prophylaxis

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Management of hepatitis B reactivation in patients receiving cancer chemotherapy'. Together they form a unique fingerprint.

Cite this